Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182–185

Sunitinib (SU11248) is an orally bioavailable inhibitor that affects the receptor tyrosine kinases involved in tumour proliferation and angiogenesis, including vascular endothelial growth factor (vegf) receptors 1, 2, 3, and platelet-derived growth factor receptors alpha (pdgfra) and beta (pdgfrb)....

Descripción completa

Detalles Bibliográficos
Autores principales: Buckstein, R., Meyer, R.M., Seymour, L., Biagi, J., MacKay, H., Laurie, S., Eisenhauer, E.
Formato: Texto
Lenguaje:English
Publicado: Multimed Inc. 2007
Materias:
Canadian Centre Activities
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1948864/
https://www.ncbi.nlm.nih.gov/pubmed/17710208

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1948864/
https://www.ncbi.nlm.nih.gov/pubmed/17710208

Ejemplares similares